Analyst consensus rating
Trevi Therapeutics Analyst Rating: none
TRVI is rated none by 11 analysts with a $28.18 target. As of 2026-08-30.
Direct answer
Trevi Therapeutics's consensus rating is none.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $28.18.
Forecast evidence checked August 30, 2026.
Get free Trevi Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $16.79
- Average price target
- $28.18
- High price target
- $40.00
- Low price target
- $23.00
- Low target gap
- +37%
- Target upside
- +67.8%
- High target gap
- +138.2%
- Target range width
- 101.3%
- Consensus rating
- none
- Analysts
- 11
- Evidence date
- August 30, 2026
- Valid through
- September 6, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Trevi Therapeutics?
Trevi Therapeutics has a verified none consensus. The same dataset has an average price target of $28.18.
How far are Trevi Therapeutics's low and high targets from the recorded price?
The low target implies +37%, while the high target implies +138.2%.
How many analysts are included in Trevi Therapeutics's consensus?
The verified consensus includes 11 analysts.
How is Trevi Therapeutics's target upside or downside calculated?
The average target of $28.18 is divided by the recorded price of $16.79, then one is subtracted to produce +67.8%. This does not guarantee a future return.
When was Trevi Therapeutics's analyst forecast verified?
The data was verified on 2026-08-30. The dataset is valid through 2026-09-06.